TRENDING :  Market Movers  |  Top 50   SPY (0.88%)    CGC (-1.42%)    CASY (0.88%)    BABA (1.16%)    BA (-0.02%)    ATVI (2.76%)    ARCW (3.48%)    APC (0.11%)    SCIF (-0.33%)    RYAAY (-2.06%)    RIOT (9.52%)    PG (-3.34%)    PANW (0.49%)    PAGS (1.48%)    MU (-0.86%)    MMYT (-0.74%)    MJ (-0.19%)    MHK (1.63%)    MBRX (-45.31%)    INTC (-0.15%)    GOOGL (1.37%)    GDXJ (-0.11%)    FRT (0.88%)    FIS (0.77%)    EWZ (1.29%)

 EXEL - Exelixis

$21.09 [0.49][2.33%]

Next Earnings

5/1/2019

AMC

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $23.00
Low $23.00
Average $23.00
Current $21.09

CompanyAnalyst NamePT ActionActionRatingTargetDate
BMO CapitalAnnouncesInitiates Coverage OnBuy$23.0002/22/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $EXEL

TRENDING ARTICLES



3 Cancer Treatment Stocks to Buy in April

04/20/19
Cancer drug sales are on track to eclipse the 200 billion mark early in the next decade thanks to an innovation bonanza that s transformed oncology into the fastest growing segment across the entire pharmaceutical industry Specifically a recen t report by EvaluatePharma

Exelixis is Now Oversold (EXEL)

04/18/19
Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on

ProQR Initiates Dosing in Phase II/III Eye Disorder Study

04/17/19
ProQR Therapeutics N V PRQR announced that it has started dosing patients in the phase II III study ILLUMINATE evaluating its RNA based candidate sepofarsen QR 110 for an eye disorder Leber s congenital amaurosis 10 LCA10 The ILLUMINATE study will enroll 30 patients in three

Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock

04/11/19
InvestorPlace Stock Market News Stock Advice amp Trading Tips If you re asking whether or not to buy Exelixis NASDAQ EXEL stock the answer is it depends But if you re a risk tolerant investor in search of an up and coming biotech doing more than a few things

First Week of EXEL November 15th Options Trading

04/10/19
Investors in Exelixis Inc Symbol EXEL saw new options become available this week for the November 15th expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 219 days until expiration the newly available contracts represent

8 Stocks to Buy That Are Growing Faster Than Amazon

04/08/19
InvestorPlace Stock Market News Stock Advice amp Trading Tips Editor s note This story was previously published in February 2019 It has since been updated and republished Do you think Amazon com 160 NASDAQ AMZN is a growth machine like no other and one of

Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?

04/06/19
Shares of Exelixis Inc EXEL have rallied 22 4 in the year so far outperforming 14 6 growth registered by the industry The company received a major boost with the approval of a tablet formulation of cabozantinib Cabometyx which was approved in the United States in April

After Hours Most Active for Apr 3, 2019 : CMCSA, BBD, PARR, BAC, CNHI, EBAY, MSFT, UAL, AES, SYF, ACHC, EXEL

04/03/19
The NASDAQ 100 After Hours Indicator is up 2 81 to 7 547 78 The total After hours volume is currently 86 829 800 shares traded The following are the most active stocks for the after hours session Comcast Corporation CMCSA is unchanged at 40 27 with 4 462 782

The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

04/01/19
For Immediate Release Chicago IL April 1 2019 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include

Biotech Stocks Outperform During Inversions: 5 Must Watch

03/29/19
Traditionally an inverted yield curve indicates a recession in a year or two And that surely is a bearish signal for the Wall Street But biotech stocks tend to outdo during a period of inverted yield curves Lest we forget the yield curve inverted on Mar 22 2019 for the first time